Find more staff
Role:
Department staff:
Research staff:
- Position:Wallscourt Senior Research Fellow
- Department:School of Applied Sciences
- Email:Daniel.Turnham@uwe.ac.uk
-
Social media:
About me
I am a Senior Research Fellow funded by the Wallscourt foundation. My research primarily focuses on developing new therapeutic strategies to treat advanced prostate cancers, with a particular interest in overcoming therapeutic resistance. I completed my undergraduate training at the University of Liverpool before moving to Cardiff University to complete my PhD which focused on 'Investigating the role of Bcl-3 in metastatic breast cancer and the use of novel Bcl-3 inhibitors as a potential therapeutic.' Following this I undertook postdoctoral positions at Cardiff and Swansea Universities where I was heavily involved in the preclinical development of novel agents designed to target and treat advanced prostate cancers.
Area of expertise
My current research is predominately focused on:
Developing new therapeutic strategies to target aggressive, hard to treat prostate cancer
Identifying novel therapeutic targets and performing preclinical evaluation of new agents, with distinct modalities of tumour killing, to improve patient outcomes.
Investigating the fundamental molecular mechanisms that drive tumour progression and therapeutic resistance.
Improving our understanding of what drives tumour progression and treatment resistance to help identify new therapeutic opportunities and help to validate targets that are already known.
Expanding the number of clinically relevant tumour models that represent the types of cancer observed in patients.
Using preclinical models that mimic the range of inter and intra tumour heterogeneity observed in the clinic to successfully translate preclinical findings and guide the design of future early phase clinical trials to aid patient care.
I am always keen to develop new collaborative projects both within and outside these core interests.
Funding Awards:
PCUK Research Innovation Award (2023)- Investigating BCL3 as a therapeutic target to treat prostate cancer- £518,203, 3-year award. CoI
Cardiff University Biosciences Seedcorn Award (2022) - Developing the chick chorioallantoic membrane assay as a new clinically relevant model of prostate cancer- £3,379.80, 9-month award. PI
Wellcome Trust Translation Partnership Award: Translation of concept fund (2022)- Investigating RAGE-ADC as a new theranostic approach for prostate cancer- £19,745, 1-year award. Co-PI
Cardiff DEVAR Cancer Research Equipment Fund (2022)- IncuCyte Live-cell 3D Organoid Analysis Platform: a new approach to standardise assay analysis- £38,515.50. CoI
Cardiff University Biosciences Seedcorn Award (2022) - Investigating how Bcl-3 loss initiates apoptosis and senescence in breast cancer- £3,160.81, 9-month award. PI
Future Leaders of Cancer Research (2022) - Preclinical evaluation of RAGE-targeting ADCs to treat prostate cancer. Seedcorn Funding Awarded - £7,614.44, 1-year award. PI
Innovation Award (2021)- Preclinical evaluation of RAGE-targeting ADCs to treat prostate cancer. Impact Fund: Kickstart Funding Awarded - £7,890.00, 1-year award. Co-PI
Publications
Publications loading...